Properties of An Oral Nanoformulation of A Molecularly Dispersed Amphotericin B Comprising A Composite Matrix of Theobroma Oil and Bee'S Wax

• Published in: Nanomaterials (Basel, Switzerland) Vol. 4; no. 4; pp. 905 - 916
• Main Authors: Tan, Chloe See Wei, Billa, Nashiru, Roberts, Clive J, Scurr, David J
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 19.12.2014; MDPI
• Subjects: amphotericin B (AmB); Beeswax; Bioavailability; cellular uptake; Dispersion; Drug delivery systems; Encapsulation; Fungal infections; lipid; Lipids; Lymph; Nanomaterials; Nanoparticles; Nanostructure; Oral administration; Pharmacy; Shells; Spectrum analysis; theobroma oil; Uptakes; United Kingdom > UK; Malaysia; amphotericin B (AmB); nanoparticles; beeswax; lipid; theobroma oil; cellular uptake
• ISSN: 2079-4991; 2079-4991
• DOI: 10.3390/nano4040905

An amphotericin B-containing (AmB) solid lipid nanoparticulate drug delivery system intended for oral administration, comprised of bee's wax and theobroma oil as lipid components was formulated with the aim to ascertain the location of AmB within the lipid matrix: (a) a homogenous matrix; (b) a drug-enriched shell; or (c) a drug enriched core. Both the drug-loaded and drug-free nanoparticles were spherical with AmB contributing to an increase in both the -average diameter (169 ± 1 to 222 ± 2 nm) and zeta potential (40.8 ± 0.9 to 50.3 ± 1.0 mV) of the nanoparticles. A maximum encapsulation efficiency of 21.4% ± 3.0%, corresponding to 10.7 ± 0.4 mg encapsulated AmB within the lipid matrix was observed. Surface analysis and electron microscopic imaging indicated that AmB was dispersed uniformly within the lipid matrix (option (a) above) and, therefore, this is the most suitable of the three models with regard to modeling the propensity for uptake by epithelia and release of AmB in lymph.